12.06
price up icon1.94%   0.23
after-market アフターアワーズ: 12.05 -0.010 -0.08%
loading
前日終値:
$11.83
開ける:
$12.08
24時間の取引高:
3.83M
Relative Volume:
0.86
時価総額:
$1.25B
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-2.2007
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
+4.55%
1か月 パフォーマンス:
+25.63%
6か月 パフォーマンス:
+26.95%
1年 パフォーマンス:
-53.78%
1日の値動き範囲:
Value
$11.86
$12.55
1週間の範囲:
Value
$11.30
$12.55
52週間の値動き範囲:
Value
$5.90
$27.42

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

NTLA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
12.06 1.19B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
10:41 AM

Is Intellia Therapeutics Inc. a good long term investmentRapidly expanding wealth - Jammu Links News

10:41 AM
pulisher
06:29 AM

What analysts say about Intellia Therapeutics Inc. stockOverwhelming financial success - Jammu Links News

06:29 AM
pulisher
03:50 AM

What drives Intellia Therapeutics Inc. stock priceUnprecedented market success - Jammu Links News

03:50 AM
pulisher
Jul 18, 2025

Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-profit capital plays - Jammu Links News

Jul 18, 2025
pulisher
Jul 17, 2025

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks

Jul 15, 2025
pulisher
Jul 09, 2025

Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st

Jul 09, 2025
pulisher
Jul 08, 2025

Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq

Jul 07, 2025
pulisher
Jul 07, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus

Jul 07, 2025
pulisher
Jul 03, 2025

Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus

Jul 03, 2025
pulisher
Jul 03, 2025

Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey

Jul 03, 2025
pulisher
Jul 02, 2025

Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus

Jul 02, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jun 28, 2025

Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN

Jun 28, 2025
pulisher
Jun 25, 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 23, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey

Jun 23, 2025
pulisher
Jun 22, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance

Jun 22, 2025
pulisher
Jun 21, 2025

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance

Jun 21, 2025
pulisher
Jun 18, 2025

Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News

Jun 18, 2025
pulisher
Jun 17, 2025

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener

Jun 16, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients - Quiver Quantitative

Jun 15, 2025
pulisher
Jun 14, 2025

Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 10, 2025

California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World

Jun 10, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView

Jun 04, 2025
pulisher
Jun 04, 2025

Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus

Jun 03, 2025

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Intellia Therapeutics Inc (NTLA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Dube Michael P
VP, Chief Accounting Officer
Jul 02 '25
Sale
9.95
2,503
24,905
57,137
GOODMAN JESSE
Director
Jun 30 '25
Sale
9.56
1,547
14,789
25,906
GOODMAN JESSE
Director
Jul 01 '25
Sale
9.23
1,547
14,279
24,359
Bhanji Muna
Director
Apr 29 '25
Sale
8.50
265
2,252
19,203
Clark Eliana
EVP, Chief Technical Officer
Mar 04 '25
Sale
8.99
679
6,104
95,369
BASTA JAMES
EVP, General Counsel
Mar 04 '25
Sale
8.99
2,572
23,122
111,925
Bhanji Muna
Director
Jan 29 '25
Sale
9.97
265
2,642
19,468
Dube Michael P
VP, Chief Accounting Officer
Jan 03 '25
Sale
12.18
1,372
16,711
45,640
BASTA JAMES
EVP, General Counsel
Jan 03 '25
Sale
12.18
7,074
86,161
74,497
Lebwohl David
EVP, Chief Medical Officer
Jan 03 '25
Sale
12.18
9,557
116,404
87,666
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
大文字化:     |  ボリューム (24 時間):